Table 2. MGr1-Ag/37LRP siRNA attenuates multi-drug-resistance in PrPC derived gastric cancer cells (IC50 of drugs).
| Cell lines | Treatment | 5-FU | CDDP | ADR | VCR | |
|---|---|---|---|---|---|---|
| 7LRP siRNA | siRNA NC | |||||
| SGC7901/PrP | – | + | 0.13 ± 0.01 | 1.88 ± 0.26 | 1.57 ± 0.18 | 7.49 ± 1.27 |
| + | – | 0.06 ± 0.01† | 0.19 ± 0.06† | 0.84 ± 0.11† | 4.41 ± 0.19† | |
| SGC7901/VCR | – | + | 1.88 ± 0.57 | 5.27 ± 0.54 | 3.77 ± 0.46 | 17.42 ± 2.09 |
| + | – | 0.55 ± 0.10‡ | 1.63 ± 0.28‡ | 1.94 ± 0.27‡ | 7.53 ± 0.51‡ | |
†p < 0.05 vs. SGC7901/PrP cells transfected with siRNA negative control.
‡p < 0.05 vs. SGC7901/VCR cells transfected with siRNA negative control.